ID: ALA540105

Max Phase: Preclinical

Molecular Formula: C23H24Cl2N4O4S

Molecular Weight: 486.98

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1ccc(NS(=O)(=O)c2ccc(Cl)cc2)c(O)c1CC(=O)NCc1ccc(C(=N)N)cc1.Cl

Standard InChI:  InChI=1S/C23H23ClN4O4S.ClH/c1-14-2-11-20(28-33(31,32)18-9-7-17(24)8-10-18)22(30)19(14)12-21(29)27-13-15-3-5-16(6-4-15)23(25)26;/h2-11,28,30H,12-13H2,1H3,(H3,25,26)(H,27,29);1H

Standard InChI Key:  VTQJWQCYLDWTPH-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 486.98

Molecular Weight (Monoisotopic): 486.1129

AlogP: 3.30

#Rotatable Bonds: 8

Polar Surface Area: 145.37

Molecular Species: BASE

HBA: 5

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 7.17

CX Basic pKa: 11.43

CX LogP: 3.36

CX LogD: 3.17

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.19

Np Likeness Score: -1.19

References

1. Hanessian S, Therrien E, van Otterlo WA, Bayrakdarian M, Nilsson I, Fjellström O, Xue Y..  (2006)  Phenolic P2/P3 core motif as thrombin inhibitors--design, synthesis, and X-ray co-crystal structure.,  16  (4): [PMID:16290930] [10.1016/j.bmcl.2005.10.082]

Source

Source(1):

• Scientific Literature